A Delaware jury found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents belonging to Scale Biosciences—acquired by 10x Genomics in 2025—while also upholding those patents’ validity. The jury awarded 10x over $4.8 million in damages tied to Parse’s Evercode Whole Transcriptome product sales and based on a 14% royalty rate. The verdict also supported a move to stop further infringement via permanent injunction during post-trial proceedings. The ruling deepens an ongoing legal battle around ownership and freedom-to-operate for single-cell methods and barcoding workflows.